The global pandemic of COVID-19 continues to be an important threat, especially with
the fast transmission rate observed after the discovery of novel mutations. In this
perspective, prompt diagnosis requires massive economical and human resources to
mitigate the disease. The current study proposes a rational design of a colorimetric
lateral flow immunoassay (LFA) based on the repurposing of human samples to produce
COVID-19-specific antigens and antibodies in combination with a novel dye-loaded
polymersome for naked-eye detection. A group of 121 human samples (61 serums and 60
nasal swabs) were obtained and analyzed by RT-PCR and ELISA. Pooled samples were used to
purify antibodies using affinity chromatography, while antigens were purified
via
magnetic nanoparticles-based affinity. The purified proteins were
confirmed for their specificity to COVID-19
via
commercial LFA, ELISA,
and electrochemical tests in addition to sodium dodecyl sulfate-polyacrylamide gel
electrophoresis analysis. Polymersomes were prepared using methoxy polyethylene
glycol-
b
-polycaprolactone (mPEG-
b
-PCL) diblock
copolymers and loaded with a Coomassie Blue dye. The polymersomes were then
functionalized with the purified antibodies and applied for the preparation of two types
of LFA (antigen test and antibody test). Overall, the proposed diagnostic tests
demonstrated 93 and 92.2% sensitivity for antigen and antibody tests, respectively. The
repeatability (92–94%) and reproducibility (96–98%) of the tests highlight
the potential of the proposed LFA. The LFA test was also analyzed for stability, and
after 4 weeks, 91–97% correct diagnosis was observed. The current LFA platform is
a valuable assay that has great economical and analytical potential for widespread
applications.